Clinical Trials Browser

Phase 2/3 × Epstein-Barr Virus Infections × Clear all

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05305040 2024-05-16

Prevent

Phase 2/3 Terminated

451 enrolled 10 charts

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT04693637 2024-05-09

Prevent

Phase 2/3 Completed

26 enrolled 16 charts

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections